Naveenchandra Suryadevara

The paper investigates how IGHV3-53/3-66 antibodies from Omicron BA.1 infection neutralize emerging SARS-CoV-2 variants through structural and mutational analysis.

The paper isolates glycan-reactive antibodies from HIV-1 vaccine trial participants and finds they neutralize diverse HIV strains and show broad cross-reactivity against other pathogens.

This study identifies a monoclonal antibody that neutralizes HCoV-HKU1 by mimicking sialic acid binding to block receptor engagement.

This paper develops a mouse model of SARS-CoV-2 BA.5 infection that induces fibrotic lung disease and tertiary lymphoid structures, enabling study of acute and post-acute sequelae of COVID-19.

This study uses high-throughput screens in human cells with authentic SARS-CoV-2 virus to identify neutralizing monoclonal antibodies and kinase inhibitors with minimal host toxicity.

The paper identifies a pan-betacoronavirus antibody that binds the S2 subunit of spike proteins and induces Fc-dependent antiviral responses, offering insights into non-neutralizing antibody protection.